News

NEW YORK, NY, December 17, 2020 – Royalty Pharma (Nasdaq: RPRX) and The Rockefeller University announced generous gifts totaling $5,760,000 from Royalty Pharma and Pablo and Almudena Legorreta. Half of the gift will be donated by Royalty Pharma and the other half by Pablo and Almudena Legorreta

NEW YORK, NY and RESEARCH TRIANGLE PARK, N.C, December 7, 2020 – Royalty Pharma (Nasdaq: RPRX), BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) and Athyrium Capital Management, LP today announced transactions totaling $325 million in funding for BioCryst, with $250 million available at closing, to

NEW YORK, NY, November 2, 2020 - Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement to acquire the residual royalty interest in Vertex Pharmaceuticals, Inc.’s cystic fibrosis (CF) treatments owned by the Cystic Fibrosis Foundation. The agreement includes an upfront payment of $575

NEW YORK , Oct. 20, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc (the “Company”) (Nasdaq: RPRX) announced today the closing of the secondary offering of 17,343,037 shares of its Class A ordinary shares by selling shareholders in an underwritten public offering at a price to the public of $42.00 per

NEW YORK , Oct. 19, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma (Nasdaq: RPRX) today announced that it will report its third quarter 2020 financial results on Wednesday, November 11, 2020 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00

NEW YORK, NY – October 15, 2020 – Royalty Pharma plc (the “Company”) (Nasdaq: RPRX) announced today the pricing of the secondary offering of 17,343,037 shares of its Class A ordinary shares by selling shareholders in an underwritten public offering pursuant to a registration statement on Form S-1

NEW YORK , Oct. 15, 2020 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2020 of $0.15 per class A share. The dividend will be paid on December 15, 2020 , to shareholders of record at the close of

NEW YORK , Oct. 13, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc (the “Company”) (Nasdaq: RPRX) announced today that certain selling shareholders intend to offer an aggregate 17,343,037 of the Company's Class A ordinary shares in an underwritten public offering.

NEW YORK, NY, September 2, 2020 - The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2020 of $0.15 per class A share. The dividend will be paid on September 30, 2020, to shareholders of record at the close of business on